Compliant GLP-1 API Sourcing from a Vetted cGMP Network

One platform, transparent credentials, market-aligned supply — 4 FDA DMFs and 20+ peptide APIs from screened Chinese cGMP manufacturers.

4 FDA DMFs Filed NDC Listed 20+ Peptide APIs cGMP · Batch COA

Vetted Supplier Network

Factories screened for GMP, DMF validity, capacity and import-alert status.

NDC Listed

Products registered under FDA NDC labeler codes 83589 & 83821.

20+ Peptide APIs

GLP-1 analogues, growth-hormone secretagogues, research peptides and biomedicinal enzymes.

Batch-Level COA

Certificate of Analysis issued for every batch, with full export documentation support.

Product Platform — Four Lines

One platform, full coverage: from regulatory-ready GLP-1 APIs to research peptides and biomedicinal enzymes.

GLP-1 analogue peptide molecule 4 FDA DMFs

GLP-1 Analogues

Semaglutide, liraglutide, tirzepatide, retatrutide (all with FDA DMF), plus cagrilintide and eloralintide.

  • Regulatory-ready: DMF authorization for your registration
  • Commercial supply in patent-expired markets
growth hormone secretagogue peptide RUO / Registered

Growth-Hormone Secretagogues

Sermorelin, tesamorelin, ipamorelin, CJC-1295 and CJC-1295 with DAC.

  • Available at 97–98% purity
  • For licensed manufacturers and research use
peptide research laboratory Research Use

Research Peptides

BPC-157, AOD-9604, IGF-1 LR3, MOTS-C, bremelanotide (PT-141), thymosin α1 and β4.

  • For R&D and qualified research institutions
  • Patent-protected products supplied for research only
enzyme protein structure Biomedical

Biomedicinal Enzymes

Recombinant carboxypeptidase B and recombinant KexII protease for biopharmaceutical manufacturing.

  • Process enzymes with defined activity specs
  • cGMP-compatible supply

How We Vet Suppliers

Every manufacturer in our network passes a four-step qualification before its products go live on the platform.

Step 1

Documentation Review

GMP certificates, business licenses, DMF validity and export qualifications are verified against official records — including FDA import-alert status.

Step 2

Sample Testing

Batch samples and COAs are reviewed against specifications, with third-party testing where required.

Step 3

Facility Audit

On-site or video audits cover production lines, QC laboratories and warehousing.

Step 4

Trial Order

Small-batch trial orders verify quality, delivery and documentation before listing.

Market-Ready Supply Strategy

We align supply to each market's patent and regulatory status, so your sourcing is compliant from day one.

Open Now

Brazil

Semaglutide compound patent expired March 2026. ANVISA has approved first generic pens — local manufacturers are scaling production.

  • Supply to ANVISA-registered manufacturers
  • Full dossier & DMF support
Opens ~April 2027

Australia

Generic-entry window opens in April 2027. We are building partnerships with licensed manufacturers now.

  • Partner agreements for 2027 launch
  • Research-use supply available today
US: RUO until Dec 2031

United States

Semaglutide's compound patent restricts US use to research until December 2031; supply to the US is verified per supplier import status.

  • Research use only (patent) until Dec 2031
  • US supply evaluated per vetted supplier status

Why Source With GLPION

Request the Full Catalog & Documentation

Tell us your market and target molecules — we will respond with specifications and COA samples.

Contact Our Export Team